Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AGIO NASDAQ:ARVN NASDAQ:HRMY NASDAQ:IDYA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAGIOAgios Pharmaceuticals$37.71-1.2%$37.12$23.42▼$62.58$2.22B0.8936,872 shs502,787 shsARVNArvinas$7.73-0.4%$7.48$5.90▼$29.61$569.72M2.221.93 million shs735,457 shsHRMYHarmony Biosciences$36.89-2.8%$34.98$26.47▼$41.61$2.18B0.84522,924 shs474,415 shsIDYAIDEAYA Biosciences$24.55-1.5%$23.26$13.45▼$40.25$2.18B0.09877,057 shs632,810 shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAGIOAgios Pharmaceuticals-1.23%-2.81%+0.45%+16.42%-16.87%ARVNArvinas-0.39%+5.60%+1.98%+6.92%-70.00%HRMYHarmony Biosciences-2.84%-2.56%+3.97%+7.30%+4.03%IDYAIDEAYA Biosciences-1.52%-2.27%-3.16%+22.44%-37.99%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAGIOAgios Pharmaceuticals4.3618 of 5 stars3.42.00.04.33.20.81.9ARVNArvinas3.9305 of 5 stars4.33.00.00.03.02.51.3HRMYHarmony Biosciences4.6478 of 5 stars3.53.00.00.03.03.34.4IDYAIDEAYA Biosciences4.5051 of 5 stars4.43.00.04.43.11.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAGIOAgios Pharmaceuticals 2.75Moderate Buy$56.3349.39% UpsideARVNArvinas 2.55Moderate Buy$19.76155.67% UpsideHRMYHarmony Biosciences 3.00Buy$51.0038.25% UpsideIDYAIDEAYA Biosciences 2.75Moderate Buy$47.1091.85% UpsideCurrent Analyst Ratings BreakdownLatest ARVN, IDYA, AGIO, and HRMY Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/7/2025ARVNArvinasHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$24.00 ➝ $18.008/7/2025ARVNArvinasWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$19.00 ➝ $16.008/7/2025ARVNArvinasGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.007/28/2025AGIOAgios PharmaceuticalsScotiabankSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSector Outperform ➝ Sector Outperform$71.00 ➝ $65.007/28/2025IDYAIDEAYA BiosciencesJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$66.00 ➝ $72.007/22/2025AGIOAgios PharmaceuticalsBank of AmericaSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$52.00 ➝ $51.007/22/2025IDYAIDEAYA BiosciencesTD CowenSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy7/21/2025HRMYHarmony BiosciencesTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$48.007/10/2025HRMYHarmony BiosciencesDeutsche Bank AktiengesellschaftSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$54.00 ➝ $55.007/10/2025HRMYHarmony BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$33.007/10/2025IDYAIDEAYA BiosciencesThe Goldman Sachs GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold$25.00(Data available from 8/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAGIOAgios Pharmaceuticals$36.50M60.03N/AN/A$23.57 per share1.60ARVNArvinas$263.40M2.15N/AN/A$8.30 per share0.93HRMYHarmony Biosciences$714.73M2.97$2.86 per share12.89$13.44 per share2.74IDYAIDEAYA Biosciences$7M307.37N/AN/A$10.95 per share2.24Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAGIOAgios Pharmaceuticals$673.72M$11.003.43N/AN/A1,590.42%-3.49%-3.23%10/30/2025 (Estimated)ARVNArvinas-$198.90M-$1.01N/AN/AN/A-19.47%-12.01%-6.97%10/29/2025 (Estimated)HRMYHarmony Biosciences$145.49M$3.1011.9011.860.4423.44%26.34%17.71%11/4/2025 (Estimated)IDYAIDEAYA Biosciences-$274.48M-$3.79N/AN/AN/AN/A-31.42%-29.45%11/3/2025 (Estimated)Latest ARVN, IDYA, AGIO, and HRMY EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2025Q2 2025ARVNArvinas-$0.87-$0.84+$0.03-$0.84$34.42 million$22.40 million8/5/2025Q2 2025HRMYHarmony Biosciences$0.78$0.68-$0.10$0.68$204.37 million$200.49 million8/5/2025Q2 2025IDYAIDEAYA Biosciences-$0.85-$0.88-$0.03-$0.88$3.48 million$6.00 million7/31/2025Q2 2025AGIOAgios Pharmaceuticals-$1.74-$1.93-$0.19-$1.93$9.46 million$12.50 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAGIOAgios PharmaceuticalsN/AN/AN/AN/AN/AARVNArvinasN/AN/AN/AN/AN/AHRMYHarmony BiosciencesN/AN/AN/AN/AN/AIDYAIDEAYA BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAGIOAgios PharmaceuticalsN/A14.4814.04ARVNArvinasN/A5.645.64HRMYHarmony Biosciences0.203.843.80IDYAIDEAYA BiosciencesN/A12.3912.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAGIOAgios PharmaceuticalsN/AARVNArvinas95.19%HRMYHarmony Biosciences86.23%IDYAIDEAYA Biosciences98.29%Insider OwnershipCompanyInsider OwnershipAGIOAgios Pharmaceuticals4.30%ARVNArvinas4.73%HRMYHarmony Biosciences23.60%IDYAIDEAYA Biosciences2.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAGIOAgios Pharmaceuticals39058.10 million55.60 millionOptionableARVNArvinas42073.42 million69.95 millionOptionableHRMYHarmony Biosciences20057.53 million43.96 millionOptionableIDYAIDEAYA Biosciences8087.64 million85.45 millionOptionableARVN, IDYA, AGIO, and HRMY HeadlinesRecent News About These CompaniesIDEAYA Biosciences, Inc.: IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)5 hours ago | finanznachrichten.deIDEAYA Biosciences to Present First Median Overall Survival Data from Phase 2 Trial of the Darovasertib / Crizotinib Combination in Metastatic Uveal Melanoma at the 2025 Society for Melanoma Research CongressAugust 29 at 2:00 PM | prnewswire.comIDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)August 29 at 6:00 AM | prnewswire.comIDEAYA Biosciences, Inc. $IDYA Shares Bought by Jump Financial LLCAugust 29 at 5:19 AM | marketbeat.comAlphaQuest LLC Boosts Stake in IDEAYA Biosciences, Inc. $IDYAAugust 29 at 4:57 AM | marketbeat.comPrice T Rowe Associates Inc. MD Reduces Stock Position in IDEAYA Biosciences, Inc. $IDYAAugust 29 at 4:06 AM | marketbeat.comNuveen LLC Acquires New Holdings in IDEAYA Biosciences, Inc. $IDYAAugust 29 at 3:36 AM | marketbeat.comVanguard Group Inc. Purchases 14,535 Shares of IDEAYA Biosciences, Inc. $IDYAAugust 26, 2025 | marketbeat.comIDEAYA Biosciences to Participate in Upcoming September 2025 Investor Relations EventsAugust 25, 2025 | prnewswire.comCandriam S.C.A. Trims Stock Position in IDEAYA Biosciences, Inc. $IDYAAugust 23, 2025 | marketbeat.comAberdeen Group plc Boosts Stock Holdings in IDEAYA Biosciences, Inc. $IDYAAugust 23, 2025 | marketbeat.comAlgert Global LLC Acquires Shares of 306,708 IDEAYA Biosciences, Inc. $IDYAAugust 21, 2025 | marketbeat.comIDEAYA Biosciences Announces Agenda for 10-Year Anniversary R&D Day on September 8, 2025August 18, 2025 | prnewswire.comIDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by Deutsche Bank AGAugust 17, 2025 | marketbeat.comRBC Capital Remains a Buy on IDEAYA Biosciences (IDYA)August 11, 2025 | theglobeandmail.comLeerink Partnrs Has Bullish Estimate for IDYA Q3 EarningsAugust 11, 2025 | marketbeat.comFY2025 EPS Estimates for IDYA Cut by Cantor FitzgeraldAugust 9, 2025 | marketbeat.comXTX Topco Ltd Acquires 17,536 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA)August 9, 2025 | marketbeat.comQ3 EPS Forecast for IDEAYA Biosciences Increased by AnalystAugust 8, 2025 | marketbeat.comGSK and Ideaya’s Promising Study on Tumor-Reducing Drug GSK4418959August 7, 2025 | msn.comIDEAYA Biosciences (NASDAQ:IDYA) Issues Quarterly Earnings Results, Misses Estimates By $0.03 EPSAugust 6, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeARVN, IDYA, AGIO, and HRMY Company DescriptionsAgios Pharmaceuticals NASDAQ:AGIO$37.71 -0.47 (-1.23%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$37.72 +0.02 (+0.04%) As of 08/29/2025 05:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias. The company develops AG-946, a PK activator for treating lower-risk myelodysplastic syndrome and hemolytic anemias; and AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria. Its preclinical product is siRNA for the treatment of polycythemia vera, a rare blood disorder. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.Arvinas NASDAQ:ARVN$7.73 -0.03 (-0.39%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$7.72 -0.01 (-0.06%) As of 08/29/2025 07:27 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.Harmony Biosciences NASDAQ:HRMY$36.89 -1.08 (-2.84%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$37.00 +0.11 (+0.30%) As of 08/29/2025 06:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.IDEAYA Biosciences NASDAQ:IDYA$24.55 -0.38 (-1.52%) Closing price 08/29/2025 04:00 PM EasternExtended Trading$24.47 -0.08 (-0.33%) As of 08/29/2025 05:43 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Ollie’s Bargain Outlet: Buy it While It’s Still a Bargain Best Buy Marketplace: Potential Growth Catalyst or Risky Gimmick? CrowdStrike at a Crossroads: AI Halo vs. Risks Snowflake’s Snowballing Business and Robust Stock Price Outlook NVIDIA's Earnings Show a Green Light for Taiwan Semiconductor NVIDIA Stock Could Pull Back in September, But Don’t Bet on It 3 Reasons Gartner Could Be the Best Buy of Q3 NIO Just Got Its Second Upgrade of the Month, and It’s Big Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
